Gossamer Bio, Inc. (GOSS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GOSS currently has 234M outstanding shares. with significant dilution risk as 154M authorized shares could dilute existing holders by 65.6%. The company has minimally diluted shareholders by 3.52% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 234.1M shares outstanding |
230M | 150M |
| Mar 17, 2026 |
10-K filing | 228.5M shares outstanding |
230M | 160M |
| Mar 17, 2026 |
POS AM filing: This POS AM filing from 2026-03-17 discusses the rights of common and preferred stockholders, including dividends, liquidation preferences, and voting rights, and describes a potential offering of preferred stock with terms to be detailed in a prospectus supplement. |
230M | 160M |
| Nov 05, 2025 |
10-Q filing | 228.0M shares outstanding |
230M | 160M |
| Aug 05, 2025 |
10-Q filing | 227.3M shares outstanding |
230M | 160M |
| May 15, 2025 |
10-Q filing | 226.8M shares outstanding |
230M | 160M |
| Mar 13, 2025 |
10-K filing | 226.2M shares outstanding |
230M | 160M |
| Nov 07, 2024 |
10-Q filing | 226.3M shares outstanding |
230M | 160M |
| Aug 12, 2024 |
10-Q filing | 226.2M shares outstanding |
230M | 160M |
| May 07, 2024 |
10-Q filing | 225.7M shares outstanding |
230M | 160M |
| Mar 05, 2024 |
10-K filing | 225.6M shares outstanding |
230M | 160M |
| Nov 09, 2023 |
10-Q filing | 225.4M shares outstanding |
230M | 160M |
| Aug 18, 2023 |
S-3 filing: This S-3 filing relates to the proposed resale or other disposition by the selling securityholders of up to 129,869,440 shares of common stock and up to 32,467,360 shares of common stock issuable upon the exercise of warrants. |
230M | 160M |
| Aug 08, 2023 |
10-Q filing | 225.3M shares outstanding |
230M | 0 |
| Jul 20, 2023 |
8-K filing: Gossamer Bio, Inc. entered into a securities purchase agreement for the private placement of 129,869,440 shares of common stock and accompanying warrants to purchase up to 32,467,360 shares of common stock at a combined price of $1.63125 per Share and accompanying Warrant, or with respect to any Purchaser that is an officer, director, employee or consultant of the Company $1.85125 per Share and accompanying Warrant. ($212.1M proceeds) |
95M | 0 |
| May 09, 2023 |
10-Q filing | 94.9M shares outstanding |
95M | 0 |
| Mar 17, 2023 |
10-K filing | 95.0M shares outstanding |
95M | 0 |
| Nov 03, 2022 |
10-Q filing | 91.2M shares outstanding |
91M | 0 |
| Aug 09, 2022 |
10-Q filing | 94.0M shares outstanding |
94M | 0 |
| Jul 13, 2022 |
8-K filing: Gossamer Bio, Inc. entered into a stock purchase agreement for the private placement of 16,649,365 shares of common stock at $7.21 per share, with aggregate gross proceeds of approximately $120.0 million. ($120.0M proceeds) |
76M | 0 |
| May 10, 2022 |
10-Q filing | 75.9M shares outstanding |
76M | 0 |
| Mar 03, 2022 |
10-K filing | 74.8M shares outstanding |
75M | 0 |
| Nov 08, 2021 |
10-Q filing | 75.0M shares outstanding |
75M | 0 |
| Aug 09, 2021 |
10-Q filing | 74.7M shares outstanding |
75M | 0 |
| May 06, 2021 |
10-Q filing | 74.1M shares outstanding |
74M | 0 |
| Feb 26, 2021 |
10-K filing | 75.5M shares outstanding |
76M | 0 |
| Nov 10, 2020 |
10-Q filing | 75.9M shares outstanding |
76M | 0 |
| Aug 11, 2020 |
10-Q filing | 75.8M shares outstanding |
76M | 0 |
| May 12, 2020 |
10-Q filing | 66.4M shares outstanding |
66M | 0 |
| Mar 24, 2020 |
10-K filing | 66.3M shares outstanding |
66M | 0 |